TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02912936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic medium chain triglyceride drink (MCT drink)
Description: 10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
Study: NCT02071498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pillbox app named ALICE
Description: Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral and written information
Description: oral and written information about the most common errors of patients
Study: NCT02157090

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Patch SOS (Hansaplast®)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Herpes vesicle patch of Compeed®
Study: NCT01260948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: 10 mg Orally Disintegrating Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept®
Description: 10 mg Orally Disintegrating Tablet
Study: NCT00640289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrogammin P
Description: Prophylaxis treatment
Study: NCT00910585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching, providing social support
Description: Active telephone and in person coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching, providing social support
Description: Active telephone and in person coaching
Study: NCT03922373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A: Benzonatate 100mg
Description: Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B: Benzonatate 200mg
Description: Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group C: Benzonatate 400mg
Description: Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
Study: NCT01685437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
Study: NCT03279575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night Shift
Description: Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graveyard Shift
Description: Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Physicians in this arm will serve as a no-contact control group.
Study: NCT04280952

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONVIVO
Description: tumor tissue with the CONVIVO system
Study: NCT01164475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte-colony stimulating factor (G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Plerixafor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weight-Based Plerixafor
Study: NCT03687424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygenation (HFNO)
Description: Experimental HFNO: O2 flow 40L/min, FiO2 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygenation (HFNO)
Description: Experimental HFNO: O2 flow 40L/min, FiO2 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygenation (HFNO)
Description: Experimental HFNO: O2 flow 40L/min, FiO2 40%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-flow nasal oxygenation (LFNO)
Description: Active comparator (LFNO): O2 flow 5L/min, FiO2 40%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-flow nasal oxygenation (LFNO)
Description: Active comparator (LFNO): O2 flow 5L/min, FiO2 40%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-flow nasal oxygenation (LFNO)
Description: Active comparator (LFNO): O2 flow 5L/min, FiO2 40%
Study: NCT01270659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl buccal tablet 100 mcg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl buccal tablet 200 mcg once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/acetaminophen
Description: Oxycodone/acetaminophen 5/325 mg once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone/acetaminophen
Description: Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
Study: NCT03004040

Intervention type: BIOLOGICAL
Intervention: Flu Vaccine

Intervention type: BIOLOGICAL
Intervention: Flu Vaccine
Study: NCT03785821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BMSO
Description: BMSO was extracted from Hualien No. 4 cultivate of bitter melon seed. BMSO were incorporated into capsules containing 0.5 g of oil. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily, resulting in daily consumption of 2.3 g alpha-ESA in the BMSO group.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: OO
Description: Olive oil (extra virgin grade) was purchased from La Espanola (Acesur, Spain). OO were incorporated into capsules containing 0.5 g of oil, identical appearance to BMSO. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily.
Study: NCT01456117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone once daily for up to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone once daily for up to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone once daily for up to 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone matching placebo once daily for up to 14 days.
Study: NCT04428749

Intervention type: DIAGNOSTIC_TEST
Intervention: Yale Swallow Protocol
Description: The YSP is a three-step method consisting of an assessment of the patient's awareness, the patient's ability to follow simple instructions and finally the patient's ability to drink 90 ml water from a cup or by straw without stopping, choking or coughing.

Intervention type: DIAGNOSTIC_TEST
Intervention: FEES (fiberoptic endoscopic evaluation of swallowing)
Description: The FEES will be performed bedside by an experienced occupational therapists. The patient will be sitting upright in a chair and be given 1) 2 spoons of applesauce, 2) 2 spoons of water, 3) several sips of water, 4) 90 ml of water. All items colored blue.~The FEES will use a single-use AMBU rhino-laryngo scope slim and the AMBU monitor. the examination will be terminated in case of aspiration below the vocal cords.
Study: NCT02049632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of axillary clearance
Study: NCT02453022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin HBr 50 mg IR Tablet
Description: Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin FB 50 mg IR Tablet
Description: Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilosec (omeprazole) 40mg Delayed-Release capsule
Description: Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
Study: NCT01416779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing Intervention
Description: Finding Balance Writing Intervention
Study: NCT01455519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone ER
Description: Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill
Study: NCT01950702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngoscope assisted lightwand intubation
Description: After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lightwand intubation
Description: After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand.
Study: NCT01753063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Expectations
Description: Baseline Expectations survey (parent/guardian and adolescents 12 and older)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Expectations
Description: 3 month follow up survey (parent/guardian and adolescents 12 and older)
Study: NCT01977833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Calorie Breakfast (BTdiet)
Description: High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Caloric Dinner (DTdiet)
Description: High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
Study: NCT04663516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: games provided by the console requiring the movement of upper body, lower body and trunk.
Study: NCT02265835

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00995878

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Focused ultrasound (MRgFUS)
Description: MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery embolization (UAE)
Description: UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
Study: NCT02207608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Add hyaluronic acid to BCG Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG (Immucist®)
Description: Usual BCG treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG (Immucist®)
Description: Usual BCG treatment
Study: NCT01466868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK2206
Description: Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms.
Study: NCT01741870

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplement
Description: Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: routine care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: routine care
Study: NCT00455871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reduced fluence photodynamic therapy with Visudyne
Description: reduced fluence photodynamic therapy with visudyne

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reduced fluence photodynamic therapy with Visudyne
Description: reduced fluence photodynamic therapy with visudyne

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Lucentis intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Lucentis intravitreal injection
Study: NCT00302471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0429
Description: Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0429
Description: Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0429
Description: Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0429
Description: Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
Study: NCT02773225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: * CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> partial or complete remission Eltrombopag and slow tapering of CSA~* 12 month after therapy start --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Eltrombopag)
Description: * CSA + Placebo, evaluation after three month therapy start regarding dose escalation~* 6 month after therapy start --\> evaluation and report of remission status of the study office --\> unblinding by study office --\> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --\> dose escalation~* 12 month after start of eltrombopag --\> evaluation and report of remission status --\> complete and partial remission --\> tapering/end of study treatment
Study: NCT01780064

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interviews with a psychologist
Description: interviews with a psychologist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires
Study: NCT03494504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.5%)
Description: Reproxalap Ophthalmic Solution (0.5%) administered once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution administered once.
Study: NCT03870243

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble CPAP
Description: To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow oxygen
Description: To see the effectiveness of low flow oxygen in children with severe pneumonia
Study: NCT00710580

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-874
Description: SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: SQ injection 50 mg BIW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: SQ placebo injections for ABT-874 and etanercept
Study: NCT03609606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326 and D337
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326 and D337
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326 and D337
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013, D326 and D337
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013
Description: Daily oral administration of 1 tablet under fasting conditions for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D013
Description: Daily oral administration of 1 tablet under fasting conditions for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326 and D337
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326 and D337
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
Study: NCT00569517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 6-CBT based sesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational
Description: subjects receive one hour of nutrition education and 5 weekly phone calls
Study: NCT00539942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arixtra (fondaparinux sodium)
Description: Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent compression devices (ICD)
Description: All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
Study: NCT03374852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRNOX
Description: mFOLFIRNOX (given immediately after CPI-613 administration):
Study: NCT02894736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix tDCS machine
Description: Soterix tDCS machine - miniCT supervised neuromodulation system